Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial
Kenneth A. Ault, MD*,
Christopher P. Cannon, MD ,
Jane Mitchell*,
John McCahan*,
Russell P. Tracy, PhD ,
William F. Novotny, MD ,
James D. Reimann, PhD and
Eugene Braunwald, MD
* Maine Medical Center Research Institute, South Portland, Maine, USA
University of Vermont School of Medicine, Burlington, Vermont, USA
Genentech Inc., South San Francisco, California, USA
Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
View larger version (31K):
[in a new window]
|
Figure 1 Changes in platelet activation with time in TIMI-12 patients. Spontaneous platelet activation and the response to zero and 1 µM ADP were significantly higher at baseline than at day 7 or day 28. **p < 0.001; *p < 0.05 compared to baseline.
|
|
View larger version (13K):
[in a new window]
|
Figure 2 Correlation of platelet activation with index events and treatments. The relationship between platelet activation at baseline and dose of ADP are shown for each index event in the upper panel, and for each primary therapy in the lower panel. Platelet activation differed significantly by index event (p < 0.001) with highest activation seen in Q-wave MI patients and lowest activation seen in unstable angina patients. Platelet activation was also higher in subjects receiving thrombolysis or primary PTCA as therapy, compared to subjects receiving neither (p < 0.001). The number of patients in each group is shown in parentheses.
|
|
|
